The information lifecycle of a drug starts already during the drug discovery phase and continues far into the future in prescription- and adverse-effect databases. In this paper, we describe the past literature and existing technology of Drug Information Systems (DIS). We develop a mapping of DIS to the phased drug lifecycle taking into account the system information contents. The mapping shows that currently there is a lack of DIS providing efficacy- and safety data in a suitable format. This lack severely hinders the possibility of physicians, researchers, as well as regulatory authorities and the pharmaceutical industry, to make quantitative analyses of efficacy and safety over a wide range of drugs.